CB-839: Updated Ph I CX-839-001 data

Updated data from a cohort of 16 evaluable patients with metastatic triple-negative breast cancer (TNBC) in the open-label, dose-escalation U.S. Phase I CX-839-001 trial showed that twice-daily 600 an...